PET / Proton Therapy confirmed effective for Prostate Cancer.

U.S. researchers suggest proton therapy -- a type of external beam radiation -- is effective for localized prostate cancer with minimal side effects.

In one study, researchers at the University of Florida in Jacksonville studied 211 men with low-, intermediate- and high-risk prostate cancer. The men were treated with proton therapy, a specialized type of external beam radiation that uses protons instead of X-rays.

Nancy Mendenhall of the university's Proton Therapy Institute said the treatment was effective and the gastrointestinal and genitourinary -- reproductive organs and the urinary system -- side effects were generally minimal.

In a second study, researchers at Massachusetts General Hospital in Boston, Loma Linda University Medical Center in Loma Linda, Calif., and the Radiation Therapy Oncology Group in Philadelphia performed a case-matched analysis comparing high-dose external beam radiation therapy using a combination of photons (X-rays) and protons with brachytherapy (radioactive seed implants).

Over three years, 196 patients received the external beam treatments. Their data was compared to 203 men of similar stages who received brachytherapy over the same time period.

"For men with prostate cancer, brachytherapy and external beam radiation therapy using photons and protons are both highly effective treatments with similar relapse rates," said Dr. John J. Coen, a radiation oncologist at Massachusetts General Hospital in Boston. "Based on this data, it is our belief that men with prostate cancer can reasonably choose either treatment for localized prostate cancer based on their own concerns about quality of life without fearing they are compromising their chance for a cure."

The findings were published in the International Journal of Radiation Oncology

HPV has replaced tobacco use as the #1 cause of oral cancer.

NewsRx.com

04-15-11

A serious change in the cause of oral cancer is taking place nationally, and its implications are impacting the American public in a manner that a decade ago no one would have predicted (see also Oral Cancer).

For decades, oral cancer (also known as mouth cancer, tongue cancer, tonsil cancer, and throat cancer) has been a disease which most often occurred in older individuals, who during their lifetimes had been tobacco users. Most cases were ultimately the result of lifestyle choices. Today that paradigm has changed. A common, sexually transferred virus has replaced tobacco as the number one cause of oral cancers, Human Papilloma Virus number 16 (HPV16). This is one of the same viruses that are responsible for the majority of cervical cancers in women.

This year alone, approximately 37,000 Americans will be newly diagnosed with oral cancer, and one person will die every hour of every day from this disease. HPV16, one of about 130 versions of the virus, is now the leading cause of oral cancer, and is found in about 60% of newly diagnosed patients. Dr. Maura Gillison from the James Cancer Center, a long time researcher of the relationship between HPV and oral cancers, recently reported these new findings at the American Academy for the Advancement of Science meeting.

This change in etiology, which has accelerated its influence over the last two decades as tobacco use in the US simultaneously was declining, has also changed the demographics of who is getting the disease. It is no longer the domain of those over 50 who have smoked a decade or more of their lives. The fastest growing segment of the oral cancer population, are people in the 25-50 age range, who are never smokers, and that group predominantly comes to the disease from HPV16. Their oral cancers occur in locations anatomically unique, mostly localized to the posterior of the mouth; in the oropharynx, tonsils, and at the base of the tongue. This viral etiology makes identifying the "high risk" individual much more difficult.

Click to read more ...